Do you favor remdesivir over nirmatrelvir/ritonavir when interaction management is complex but feasible in a high-risk outpatient with early COVID-19?

Yes. If nirmatrelvir/ritonavir interactions are complex and carry meaningful risk despite being manageable, I would favor remdesivir when IV treatment is feasible.